市場調査レポート

子宮内膜症の世界市場

Endometriosis

発行 Global Industry Analysts, Inc. 商品コード 236863
出版日 ページ情報 英文 347 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
子宮内膜症の世界市場 Endometriosis
出版日: 2012年03月01日 ページ情報: 英文 347 Pages
概要

当レポートでは、世界の子宮内膜症市場について調査分析を行い、米国、カナダ、日本、欧州、世界のその他の諸国の各市場について包括的に分析し、2009年〜2017年の見通し、過去6年間の実績、主要企業などについてまとめ、概略下記の構成で取り上げております。

第1章 イントロダクション、調査方法、製品の定義

第2章 エグゼクティブサマリー

  • 産業の概要
    • 子宮内膜症の現状
    • 市場概要
    • 既存薬剤の有効性と安全性の低さが大きなニーズを生んでいる
    • 市場シナリオ
    • 将来性のある薬剤
    • パイプラインのレビュー
    • 市場見通し
  • 子宮内膜症の治療
  • 製品の概要
    • 子宮内膜症の概要
    • 女性の子宮内膜症の発症
    • 症状の原因
    • 原因
    • 子宮内膜症の症状
    • 子宮内膜症の種類
    • 生殖器子宮内膜症
    • 子宮仙骨/仙骨前神経子宮内膜症
    • ダグラス窩子宮内膜症
    • 消化器子宮内膜症
    • 呼吸器(肺/胸腔/横隔膜)子宮内膜症
    • 泌尿器(腎臓/尿管/膀胱/尿道)子宮内膜症
    • 皮膚子宮内膜症
    • 子宮内膜症のステージ
    • 子宮内膜症の診断
    • 主な診断法
    • 患者のカウンセリング
    • 子宮内膜症の再発
    • 子宮内膜症と不妊
    • 流産
    • 子宮内膜症と甲状腺自己免疫
    • 子宮内膜症と自己免疫疾患の関連
    • 子宮内膜症と癌
    • 協会と研究所
    • 子宮内膜症協会
    • 子宮内膜症研究所
  • 主な臨床試験のレビュー
  • 最近の産業活動
  • 世界の主要企業
  • 世界市場の概要

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • その他の欧州諸国
  • 世界のその他の諸国

第4章 競合状況

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MCP-6433

This report analyzes the worldwide markets for Endometriosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 32 companies including many key and niche players such as Abbott Laboratories, Aeterna Zentaris, Inc., AstraZeneca Plc, Bayer HealthCare Pharmaceuticals, Inc., Eli Lilly and Company, Meditrina Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., Pfizer, Inc., and Repros Therapeutics, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITION

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Endometriosis Fact Sheet
  • A Quick Market Primer
  • Poor Efficacy and Safety Profiles of Existing Drugs Lead to Huge Unmet Medical Needs
  • Market Scenario
  • Potential Drugs
  • The Pipeline Review
  • Market Outlook

2. TREATMENT OF ENDOMETRIOSIS

  • Endometriosis & Available Treatment Options
  • Endometriosis Treatment: In a Nutshell
  • I. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • II. Hormonal Therapy
    • Gonadotropin Releasing Hormone (Gnrh) Agonists
      • Select Major GnRH-Agonists for Endometriosis Treatment
      • Lupron, Zoladex and Synarel - The Major Drugs
      • Add-back Medication
      • Promising GnRH-antagonist Under Pipeline
      • Elagolix
    • Progestogens
      • Select Major Progestins for Endometriosis Treatment
    • Combined Oral Contraceptive Pill
    • Danazol and Other Suppressive Steroids
      • Chinese Herbs - More Effective than Danazol or Gestrinone
    • Aromatase Inhibitors
  • III. Non-hormonal Therapy
    • Anti-angiogenic Agents
    • Selective COX-2 Inhibitors
    • TNF-alpha Inhibitors
  • IV. Surgical Techniques
  • V. Complementary Therapies
    • Long-term Approach to Pain
    • Lifestyle Modifications
    • Chinese Herbs
  • Emerging Treatment for Endometriosis Treatment
  • Treatment for Endometriosis-related Infertility
  • Hormonal Treatment
    • Minimal to Mild Endometriosis
    • Moderate-Severe Endometriosis
  • Surgical Treatment
    • Minimal-Mild Endometriosis
    • Moderate-Severe Endometriosis
  • Treatment for Ovarian Endometriosis
  • Surgical Vs. Medicinal Interventions
    • Medicinal Interventions
      • Advantages
      • Disadvantages
    • Surgery
      • Advantages
      • Disadvantages
    • In-vitro Fertilization
    • Other Treatment

3. PRODUCT OVERVIEW

  • Endometriosis - An Overview
  • Occurrence of Endometriosis in Women
  • Causes and Symptoms
  • Causes
    • Estrogen Theory
    • Mullerianosis Theory
    • Retrograde Menstruation Theory
    • Coelomic Metaplasia Theory
    • Hereditary Factors
    • Environmental Factors
      • Dioxin Behavior in the Body
    • Birth Defects
    • Other Causes
  • Symptoms of Endometriosis
    • Reasons for Pain due to Endometriosis
    • Endometriosis and Infertility
  • Kinds of Endometriosis
  • Reproductive Area Endometriosis
  • Uterosacral/Presacral Nerve Endometriosis
  • Cul-de-Sac ("Pouch of Douglas") Endometriosis
  • Gastrointestinal Endometriosis
  • Pleural (lung/chest cavity/diaphragmatic) Endometriosis
  • Urinary Tract (kidneys, ureters, bladder and urethra) Endometriosis
  • Skin Endometriosis
  • Stages of Endometriosis
  • Diagnosis of Endometriosis
  • Major Diagnostic Techniques
    • Pelvic Exam
    • Laparoscopy
    • Other Diagnostic Procedures
    • A New Non-invasive Test for the Diagnosis of Endometriosis
    • Endometriosis Markers
  • Counseling of patients
  • Recurrence of Endometriosis
  • Endometriosis & Infertility
  • Miscarriage
  • Endometriosis & Thyroid Autoimmunity
  • Relationship between Endometriosis and Autoimmune Disease
  • Endometriosis & Cancer
  • Associations & Research Centers
  • The Endometriosis Association
  • Endometriosis Research Center

4. A REVIEW OF SELECT CLINICAL TRIALS

  • Neurocrine Biosciences Announces Positive Results of Phase II Daisy PETAL Study with Elagolix
  • Repros Therapeutics to Conduct Phase II Study with Five Doses of Proellex
  • Neurocrine Biosciences Announces Results from Elagolix's Phase II Tulip PETAL Study
  • Repros Therapeutics Announces Positive Results from Proellex's Phase II Clinical Study
  • Q Chip Conducts Pre-Clinical Trial for Biosimilar Q-Leuprolide, Indicated for Endometriosis and Prostrate Cancer

5. RECENT INDUSTRY ACTIVITY

  • Neurocrine and Abbott International Enter Into Collaboration Deal for Elagolix
  • Meditrina's MPI-676 Bags US Patents for Endometriosis Treatment
  • Claire Ellen Products Rolls Out ProSirona, an Endometriotic Pain-Relieving Drug
  • Bayer Schering and Protagen Sign Collaborative Contract to Develop New Biomarkers for Endometriosis
  • Gedeon Richter Acquires PregLem Holding
  • PregLem Signs In-Licensing Deal with Merck Serono
  • BMP Sunstone to Market Pfizer's Depo-Provera in China
  • Cryo-Cell International Signs Exclusive License Deal with Cryopraxis Cryobiology
  • St. Joseph's Hospital and Medical Center Signs Deal with InNexus Biotechnology
  • Cryo-Cell International and Cryopraxis Cryobiology Ink R&D Deal
  • MIT to Establish Endometriosis Investigation Center
  • Alfresa Pharma Signs Letter of Intent with Nobelpharma
  • Ardana Secures USFDA Approval for Clinical Development of Teverelix LA
  • AEterna Zentaris Announces Termination of License and Cooperation Agreement with Solvay Pharmaceuticals for Cetrorelix

6. FOCUS ON SELECT GLOBAL PLAYERS

  • Abbott Laboratories (USA)
  • AEterna Zentaris, Inc. (Canada)
  • AstraZeneca Plc. (UK)
  • Bayer HealthCare Pharmaceuticals, Inc. (USA)
  • Eli Lilly and Company (USA)
  • Meditrina Pharmaceuticals, Inc. (US)
  • Neurocrine Biosciences, Inc. (US)
  • Pfizer, Inc. (US)
  • Repros Therapeutics, Inc. (US)

7. GLOBAL MARKET PERSPECTIVE

    • Table 1: World Recent Past, Current and Future Analysis for Endometriosis by Geographic Region - US, Canada, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 2: World Historic Review for Endometriosis by Geographic Region - US, Canada, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 3: World 15-Year Perspective for Endometriosis by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Endometriosis in the US
    • Endometriosis' Research Initiatives Undertaken in the US
    • Regulatory Moves
    • Clinical Trials
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 4: US Recent Past, Current and Future Analysis for Endometriosis with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 5: US Historic Review for Endometriosis with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Select Key Players
  • B. Market Analytics
    • Table 6: Canadian Recent Past, Current and Future Analysis for Endometriosis with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 7: Canadian Historic Review for Endometriosis with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Select Key Player
  • B. Market Analytics
    • Table 8: Japanese Recent Past, Current and Future Analysis for Endometriosis with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 9: Japanese Historic Review for Endometriosis with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Endometriosis in Europe
    • Market Prospects
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 10: European Recent Past, Current & Future Analysis for Endometriosis by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 11: European Historic Review for Endometriosis by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 12: European 15-Year Perspective for Endometriosis by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart)

4a. FRANCE

  • Market Analytics
    • Table 13: French Recent Past, Current & Future Analysis for Endometriosis with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 14: French Historic Review for Endometriosis with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • EAPP in Germany
  • B. Market Analytics
    • Table 15: German Recent Past, Current & Future Analysis for Endometriosis with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 16: German Historic Review for Endometriosis with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analytics
    • Table 17: Italian Recent Past, Current & Future Analysis for Endometriosis with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 18: Italian Historic Review for Endometriosis with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Endometriosis in the UK
    • Clinical Trial
    • AstraZeneca Plc - A Key Player
  • B. Market Analytics
    • Table 19: UK Recent Past, Current & Future Analysis for Endometriosis with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 20: UK Historic Review for Endometriosis with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analytics
    • Table 21: Spanish Recent Past, Current & Future Analysis for Endometriosis with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 22: Spanish Historic Review for Endometriosis with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

4f. REST OF EUROPE

  • Market Analytics
    • Table 23: Rest of Europe Recent Past, Current & Future Analysis for Endometriosis with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 24: Rest of Europe Historic Review for Endometriosis with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

5. REST OF WORLD

  • A. Market Analysis
    • Asia-Pacific - Growing Acceptance of Herbal Treatment
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 25: Rest of World Recent Past, Current and Future Analysis for Endometriosis Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 26: Rest of World Historic Review for Endometriosis with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top